PARALLEL EVENTS (WEDNESDAY)
Separate Registration: Please, access the Registration Area to apply and pay. Or click on the “SUBSCRIBE” button below.
Free of charge to HEMO attendees (until 2 events)
Proceed with your registration at the event website.
Access the registered area to select the event and secure your registration in advance.
WEDNESDAY | OCTOBER 31st
Eduardo Magalhães Rego
I Joint Symposium of Update on Hemostasis and Thrombosis
Erich Vinicius de Paula
Brazilian Society of Cardiology
Brazilian Society of Angiology and Vascular Surgery
Course description: This symposium will address hemostasis and thrombosis issues in the intersection areas of the Hematologist, Cardiologist, Vascular Surgeon and General Practitioner, with emphasis on the diagnosis and management of venous and arterial thromboembolic events. Although they represent the leading cause of adult mortality in many countries, the approach to these conditions is grouped in different disciplines. The rise of new diagnostic and therapeutic tools has led to a significant increase in scientific knowledge in the area, thus challenging the professionals who work with these patients, particularly when the clinical presentations do not respect the artificial limits of hematology, cardiology, vascular surgery and the internal medicine. It is expected that the presence of professionals from these four areas, both as speakers and at the audience, might allow a deepening of these discussions.
Provisional format: presentations should be built upon clinical scenario illustrating prevalent and relevant issues for the practice of these four disciplines. Relevant subjects will be chosen to allow the joint discussion of clinical problems. Both periods of the day can be used to discuss conditions more related to venous thromboembolism (hematology / vascular surgery / internal medicine) in the morning, and topics related to arterial thromboses and antithrombotic drug management in the afternoon.
08:30 – 10:00: Tromboembolismo venoso: diagnóstico, fatores de risco, profilaxia
08:30 – 08:40: Opening
Speakers: Rossi Murilo da Silva e Erich Vinicius de Paula
08:40 – 09:00: Associação entre TEV e doença arterial oclusiva: o que há na literatura
Speaker: Fernanda Orsi
09:00 – 09:20: Estratificação do risco de recorrência do TEV
Speaker: Daniel Dias Ribeiro
09:20 – 09:40: A resposta inflamatória na trombose venosa profunda
Speaker: Adilson Paschoa
09:40 – 10:00: Discussion
10:00 – 10:30: Break
10:30 – 12:00: Tromboembolismo venoso: manejo
Moderators: Roberto Sacilotto e Dayse Maria Lourenço
10:30 – 10:50: Uso de DOACs em pediatria
Speaker: Soraia Rouxinol
10:50 – 11:10: Anticoagulação na gestação
Speaker: André Luiz Malavasi
11:10 – 11:30: Anticoagulações nas tromboses em sítios pouco usuais
Speaker: Marcos Areias
11:30 – 12:00: Discussion
12:00 – 13:30: Pause for lunch
13:30 – 15:00: Terapia antitrombótica: anticoagulação oral
Moderators: João Carlos de Campos Guerra e Carlos Gun
13:30 – 13:50: Anticoagulação oral na FA: conduta em pacientes especiais
Speaker: Carlos Gun
13:50 – 14:10: Anticoagulação oral nas valvopatias: conduta em situações especiais
Speaker: Dalmo Antonio Ribeiro Moreira
14:10 – 14:30: O papel da anticoagulação oral nas doenças aterotrombóticas na era dos DOACs
Speaker: Antonio Eduardo Pereira Pesaro
14:30 – 15:00: Discussion
15:00 – 15:30: Break
15:30 – 17:00: Situações especiais
Moderators: Daniel Dias Ribeiro e Otávio Rizzi Coelho
15:30 – 15:50: Variações de doses nos estudos clínicos com DOACs: como traduzir para a prática clínica?
Speaker: Dayse Maria Lourenço
15:50 – 16:10: Novos antiagregantes plaquetários: impacto na prática clínica
Speaker: Otávio Rizzi Coelho
16:10 – 16:30: AVC criptogênico: investigação e manejo
Speaker: Gisele Sampaio
16:30 – 17:00: Discussion
Update on Laboratory Hemotherapy
Alfredo Mendrone Jr.
Eugenia Maria Amorim Ubiali
Nanci Alves Salles
08:30 – 09:00: Quality management in Hemotherapy laboratories
Speaker: Ana Paula Rocha Diniz Zanelli
09:00 – 10:30: Round-table: Donors and recipients immunohematology
Moderator: to define
09:00 – 09:20: Anti-D sera selection criteria for donors and recipients RhD typing
Speaker: Lilian Castilho
09:20 – 09:40: Hemolysins or agglutinins screening in blood donors?
Speaker: Shirley Castilho
09:40 – 10:00: Management of difficult cases in multiple antibodies association
Speaker: Carla Luana Dinardo
10:00 – 10:20: Management of difficult cases in autoimmune hemolytic anemia
Speaker: Melca Barros
10:20 – 10:30: Discussion
10:30 – 11:00: Break
11:00 – 12:30: Round-table: Laboratory tests for blood-borne diseases
Moderator: to define
11:00 – 11:20: Internal Quality Control for Serology and Nat laboratories
Speaker: Márcia Otani
11:20 – 11:40: Internal Quality Control: daily and regular analysis
Speaker: Vanderleia B. Valente
11:40 – 12:00: Samples transport validation: a practical approach
Speaker: Milena B. de Oliveira
12:00 – 12:20: Ministry of Health data on external quality control of molecular and serological tests
Speaker: Priscila Murador
12:20 – 12:30: Discussion
12:30 – 14:00: Break
14:00 – 14:30: Processes validation in Hemotherapy services
Moderator: Ana Paula Rocha Diniz Zanelli
14:30 – 16:00: Round-table: Processing and quality control of blood components
Moderator: to define
14:30 – 14:50: Quality in the routine of blood components production and modification
Speaker: Edson Lara Moreto
14:50 – 15:10: Blood components storage management
Speaker: Flávia Givisiez
15:10 – 15:30: Pathogens inactivation: methods, advantages and troubles
Speaker: to define
15:30 – 15:50: Blood components quality control: sampling x reliability
Speaker: Patrícia Sierra
15:50 – 16:00: Discussion
16:00 – 16:30: Break
16:30 – 18:00: Round-table: Hemotherapy laboratories automation
Moderator: to define
16:30 – 16:50: What have we learned and improved with the serology automation
Speaker: Ana Claudia de Matos Azevedo Furlanetto
16:50 – 17:10: Automation options in donors and pre-transfusion immunohematology
Speaker: Vivian Scigliano
17:10 – 17:30: Automation of molecular tests for transfusion-transmitted diseases
Speaker: José Eduardo Levi
17:30 – 17:50: Validation of equipment, software and interfacing systems
Speaker: Nanci Salles
17:50 – 18:00: Discussion
Latin American MDS Foundation Symposium
Please, access the Registration Area to apply and pay.
We are proud to announce that on October 31st, 2018, the Myelodysplastic Syndromes (MDS) Foundation will organize its first meeting in Brazil during the Annual Congress of the Brazilian Association of Hematology and Cell Therapy: Latin American MDS Foundation Symposium.
The definition of the genetic basis of myelodysplastic syndrome has opened avenues of research and there have been remarkable advances in the last few years. Well-known experts in the field will cover different topics that span from inherited predisposition to developing myeloid malignancies to age-related clonal hematopoiesis and its clinical implications. Case-based discussions will help participants understand the clinical-decision making processes regarding diagnosis, prognostication and treatment of myelodysplastic syndromes and related disorders.
Silvia M. M. Magalhães & Mario Cazzola
AABB / ABHH Accreditation Program Audit Training:
Separate congressional registrations
Please contact this site to sign up and make the payment.
DATE / TIME / VENUE: 31/10/18 from 9:00 a.m. to 5:00 p.m. at the Transamerica Expo Center.
PURPOSE: spread the full knowledge about the use of the ABHH/AABB standards,
related to the quality management system and auditing techniques.
SPECIALISTS: ABHH consultants will present necessary steps for planning, preparing,
executing and evaluating internal and external audits.
REQUIREMENTS: The AABB/ABHH Auditors training is directed to health professionals
working in Blood Banks. Whoever takes part in the training is not automatically able to
be an assessor. To become an assessor of the hemotherapy program the applicant
must have 10 years of proven experience in hemotherapy (technical area) and 5 years
of proven experience in quality management. For cell therapy aplicants should have 5
years of proven experience in cell therapy (technical area) and 5 years of proven
experience in quality management.